denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Description:
This session will focus on recent advances and current management of T-cell and NK cell lymphomas.
Dr. Duvic will discuss the first line management of advanced or refractory mycosis fungoides and Sézary syndrome using combinations of radiation, biological or targeted therapies. She will also review the use of fusion toxins (E7777, CD3-fusion toxin), antibodies (CCR4, CD52), antibody conjugates (brentuximab vedotin) and new chemotherapies that have greater anti-tumor activity with less toxicity and immunosuppression than standard chemotherapy.
Dr. Beaven will focus her discussion on current controversies in the up-front management of peripheral T cell lymphoma, NOS and anaplastic large cell lymphoma followed by a review of drugs currently FDA approved, or in development, for relapsed /refractory T cell lymphomas.
Dr. Horwitz will discuss the presentation of some of the rare T and NK lymphomas including enteropathy associated T-cell lymphoma, hepatosplenic T-cell lymphoma, nasal NK/T cell lymphoma and subcutaneous panniculitis-like T-cell lymphoma with a focus on where “standard CHOP-like” management may apply and where alternate strategies seem preferable.